In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://brd4-targetedtherapyabbv-72345.blogdeazar.com/32207191/the-smart-trick-of-abbv-744-preclinical-studies-and-results-that-nobody-is-discussing